PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Red rsons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO 10/594,773 Application Number INFORMATION DISCLOSURE September 29, 2006 Filing Date STATEMENT BY APPLICANT Hiroshi Inooka First Named Inventor 1646 N/A Art Unit (Use as many sheets as necessary) Examiner Name Not Yet Assigned Ruixiang Li of Sheet 1 1 Attorney Docket Number 66368(46590)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				T⁵
	BA	WO-91/12022	08-22-1991	Takeda Chemical Industries, Ltd.		
	BB	WO-91/14786	10-03-1991	Takeda Chemical Industries, Ltd.		
	ВС	WO-2005/094881 A1	13.10.2005	Takeda Pharmaceutical Co., Ltd.		
	BD	WO-85/00974	14.03.1985	Hybritech., Inc.		
	BE	WO-96/00284	04.01.96	Behringwerke Aktiengesellschaft		
	BF	EP-0 467 416 A1	22.01.1992	Hybritech, Inc.		
	BG	EP-0 298 654 B1	01.06.1994	Hybrisens, Ltd.		
	ВН	JP-04-120025	21.04.1992	Tosoh Corp et al.		
	ВІ	WO-85/00974 (JP-60-502104)	14.03.1985	Hybritech, Inc.		
	BJ	JP-01-138 461 A2	05-31-1989	Hybrisens, Ltd.		
	BK	JP-03-133378	08-26-1997	Kwan et al.		
	<u> </u>	(US 5,660,978)				
	BL	JP-10-504708	01-04-2000	Neuenhofer et a.		П
		(US 6,010,868)				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>8</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	CA	Suzuki, et al. (1993) Production of Immunoreactive Pituitary Adenylate Cyclase Activiting Polypeptide (PACAP) by Human Neuroblastoma Cells, IMR-32: Detection and Characterization with Monoclonal and Polyclonal Antibodies Against Different Epitocpes of PACAP. J. Biochem, 113, 549-556.			

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Examiner	/Ruixiang Li/	Date	12/19/2008
Signature		Considered	
607499			